Recruiting

Personalized vaccine treatment for triple negative breast cancer after chemotherapy

Plain-English translation of NCT06435351 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Read our Breast Cancer research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a personalized dendritic cell vaccine—a new type of immunotherapy designed specifically for you based on your tumor's genetic makeup. After you receive chemotherapy and surgery for triple negative breast cancer, doctors will analyze your remaining tumor tissue to identify its unique characteristics. They will then create a custom vaccine tailored to your cancer and give it to you to help your immune system recognize and fight any remaining cancer cells.

Triple negative breast cancer is an aggressive type that can be difficult to treat and has a higher risk of returning even after chemotherapy and surgery. This trial exists to test whether a personalized vaccine can help your body's immune system better prevent the cancer from coming back by training it to recognize the specific mutations in your tumor.

Do you qualify?

You likely qualify if…

you have been diagnosed with stage II or III triple negative breast cancer
you have completed standard chemotherapy followed by surgery, with some tumor cells remaining after treatment
you have enough remaining tumor tissue available for genetic testing
you are at least 18 years old and in generally good health
you have no evidence of cancer that has spread to other parts of your body
if you are a woman of childbearing age, you are willing to use birth control during the study

You likely don't qualify if…

you have cancer that has spread to other parts of your body or cannot be surgically removed
you have a serious autoimmune disease or are taking medications that suppress your immune system
you are pregnant or planning to become pregnant
you have a medical condition that would make it unsafe for you to undergo a procedure to collect immune cells
you are currently enrolled in another cancer treatment study

What participation looks like

First, doctors will send your tumor tissue for genetic testing to identify the mutations that make your cancer unique. Once the vaccine is created and ready, you will receive a series of vaccine injections designed specifically for you. The researchers will monitor your health and immune response over time to see if the vaccine is safe and whether it helps prevent your cancer from returning. The study involves multiple visits to the cancer center for treatment administration and follow-up appointments.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(1 site)

United States

Moffitt Cancer Center, Tampa, Florida